Cabergoline 0.25 mg/tab – US Stock

Cabergoline 0.25 mg/tab from Hilma Biocare is an oral tablet formulation containing cabergoline as its active ingredient. It belongs to the dopamine receptor agonist group and is supplied as 0.25 mg tablets, with 10 tablets per pack.

Product Overview

Cabergoline is a dopaminergic derivative of the ergoline class. The supplied product information describes its activity at dopamine D2 receptors on lactotroph cells in the pituitary gland and its relationship to prolactin production.

The product specifications identify an active half-life of approximately 62–70 hours. Cabergoline is supplied as an oral tablet and is listed as having no water retention or aromatization.

Active Ingredient

The active ingredient is Cabergoline, a dopamine receptor agonist and dopaminergic ergoline derivative.

Dosage Form and Strength

The product is supplied as an oral tablet containing 0.25 mg of cabergoline per tablet.

Product Characteristics

According to the supplied specifications, Cabergoline has the following characteristics:

• Oral/tablet formulation
• 0.25 mg cabergoline per tablet
• Approximately 62–70-hour active half-life
• Dopamine receptor agonist classification
• No water retention listed
• No aromatization listed
• 10 tablets per pack

Product Specifications

Product Characteristics

Cabergoline is described in the supplied information as a long-acting dopamine receptor agonist. Its pharmacological activity is associated with stimulation of D2 dopamine receptors, particularly those located on lactotroph cells in the pituitary gland.

The source material discusses cabergoline in relation to prolactin management and its use among athletes and bodybuilders. Such use should not be interpreted as an established recommendation for athletic performance or as a guarantee of preventing or treating adverse effects associated with other compounds.

Reported Side Effects

The supplied product description identifies several possible adverse effects associated with Cabergoline, including:

• Headache
• Dizziness
• Nausea
• Sleepiness
• Emotional distress
• Stomach pain

Individual responses can vary. Cabergoline is a pharmacologically active medication, so potential risks, contraindications, and interactions should be evaluated with an appropriately qualified healthcare professional.

Important Information

This product contains a dopamine receptor agonist and should not be presented as a supplement or as a guaranteed method for controlling hormone levels or preventing adverse effects from other substances.

The information on this page is provided for product identification and factual specification purposes only and does not constitute personalized medical advice. No dosing recommendations, treatment protocols, cycle instructions, or stacking instructions are provided.

About Hilma Biocare USA

Cabergoline 0.25 mg/tab is part of the Hilma Biocare product range. Each tablet contains 0.25 mg of cabergoline, and the product is supplied in a 10-tablet pack as US Stock.